文献速递心律失常血脂与心血管预防

房颤患者肺静脉隔离术后口服抗凝药使用与停用的评估

Assessment of Use vs Discontinuation of Oral Anticoagulation After Pulmonary Vein Isolation in Patients With Atrial Fibrillation.
PubMed 文献 · JAMA Cardiol · 2017-01-01

IMPORTANCE: Pulmonary vein isolation (PVI) is a recommended treatment for patients with atrial fibrillation, but it is unclear whether it results in a lower risk of stroke.…

要点

  • CHA2DS2-VASc≥2患者停用华法林后卒中风险显著增加。
  • 既往缺血性卒中者停用华法林后卒中风险更高。
  • 肺静脉隔离术后高危患者不应随意停用抗凝治疗。

核心结论

  • 肺静脉隔离术后停用华法林在高危患者中不安全,尤其既往有缺血性卒中者。

研究设计与样本

  • 基于瑞典全国健康登记的回顾性队列研究,纳入2006年1月1日至2012年12月31日接受肺静脉隔离的房颤患者1585例,平均随访2.6年。

主要发现

  • 1585例患者中73.0%为男性,平均(SD)年龄59.0(9.4)岁,平均(SD)CHA2DS2-VASc评分1.5(1.4)。
  • 随访超过1年的1175例患者中,360例(30.6%)在术后第一年内停用华法林。

临床怎么用

  • 对CHA2DS2-VASc≥2的肺静脉隔离术后患者,应继续指南推荐的抗凝治疗,尤其既往有缺血性卒中者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Pulmonary vein isolation (PVI) is a recommended treatment for patients with atrial fibrillation, but it is unclear whether it results in a lower risk of stroke. OBJECTIVES: To investigate the proportion of patients discontinuing anticoagulation treatment after PVI in association with the CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years [doubled], diabetes, stroke [doubled], vascular disease, age 65-74 years, sex category [female]) score, identify factors predicting stroke after PVI, and explore the risk of cardiovascular events after PVI in patients with and without guideline-recommended anticoagulation treatment. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study was conducted using Swedish national health registries from January 1, 2006, to December 31, 2012, with a mean-follow up of 2.6 years. A total of 1585 patients with atrial fibrillation undergoing PVI from the Swedish Catheter Ablation Register were included, with information about exposure to warfarin in the national quality register Auricula. Data analysis was performed from January 1, 2015, to April 30, 2016. EXPOSURES: Warfarin treatment. MAIN OUTCOMES AND MEASURES: Ischemic stroke, intracranial hemorrhage, and death. RESULTS: In this cohort of 1585 patients, 73.0% were male, the mean (SD) age was 59.0 (9.4) years, and the mean (SD) CHA2DS2-VASc score was 1.5 (1.4). Of the 1585 patients, 1175 were followed up for more than 1 year after PVI. Of these, 360 (30.6%) discontinued warfarin treatment during the first year. In patients with a CHA2DS2-VASc score of 2 or more, patients discontinuing warfarin treatment had a higher rate of ischemic stroke (5 events in 312 years at risk [1.6% per year]) compared with those continuing warfarin treatment (4 events in 1192 years at risk [0.3% per year]) (P = .046). Patients with a CHA2DS2-VASc score of 2 or more or those who had previously experienced an ischemic stroke displayed a higher risk of stroke if warfarin treatment was discontinued (hazard ratio, 4.6; 95% CI, 1.2-17.2; P = .02 and hazard ratio, 13.7; 95% CI, 2.0-91.9; P = .007, respectively). CONCLUSIONS AND RELEVANCE: These findings indicate that discontinuation of warfarin treatment after PVI is not safe in high-risk patients, especially those who have previously experienced an ischemic stroke.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Själander S, Holmqvist F, Smith JG, et al. Assessment of Use vs Discontinuation of Oral Anticoagulation After Pulmonary Vein Isolation in Patients With Atrial Fibrillation. JAMA Cardiol. 2017. PMID: 27893055. doi:10.1001/jamacardio.2016.4179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。